Fluvastatin
- Generic Name
- Fluvastatin
- Brand Names
- Lescol
- Drug Type
- Small Molecule
- Chemical Formula
- C24H26FNO4
- CAS Number
- 93957-54-1
- Unique Ingredient Identifier
- 4L066368AS
- Background
Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prev...
- Indication
To be used as an adjunct to dietary therapy to prevent cardiovascular events. May be used as secondary prevention in patients with coronary heart disease (CHD) to reduce the risk of requiring coronary revascularization procedures, for reducing progression of coronary atherosclerosis in hypercholesterolemic patients with CHD, and for the treatment of primary ...
- Associated Conditions
- Atherosclerosis, Heterozygous Familial Hypercholesterolemia (HeFH), Mixed Dyslipidemias, Primary Hypercholesterolemia, Revascularization procedures
- Associated Therapies
- -
Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas
- Conditions
- Interventions
- First Posted Date
- 2020-02-26
- Last Posted Date
- 2020-07-27
- Lead Sponsor
- Case Comprehensive Cancer Center
- Registration Number
- NCT04285749
An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
- Conditions
- Interventions
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 153
- Registration Number
- NCT03510884
- Locations
- 🇪🇸
Investigational Site Number :7240003, Pamplona, Navarra, Spain
🇵🇱Investigational Site Number :6160002, Gdansk, Pomorskie, Poland
🇲🇽Investigational Site Number :4840007, Oaxaca, Mexico
An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 18
- Registration Number
- NCT03510715
- Locations
- 🇩🇰
Investigational Site Number 2080001, Viborg, Denmark
🇪🇸Investigational Site Number 7240001, A Coruna, Spain
🇸🇮Investigational Site Number 7050001, Ljubljana, Slovenia
Effect of Fluvastatin on Brown Fat Activity
- Conditions
- Interventions
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2018-05-31
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 17
- Registration Number
- NCT03189511
- Locations
- 🇨🇭
University Hospital of Basel, Basel, Switzerland
🇨🇭University Hospital of Zurich, PET/MR Center, Schlieren, Zurich, Switzerland
High Potency Statins and Acute Kidney Injury
- First Posted Date
- 2015-08-07
- Last Posted Date
- 2016-03-14
- Target Recruit Count
- 2067639
- Registration Number
- NCT02518516
- Locations
- 🇨🇦
Dept. of Anesthesiology, Pharmacology & Therapeutics (APT), University of British Columbia, Vancouver, British Columbia, Canada
High Potency Statins and the Risk of Diabetes
- First Posted Date
- 2015-08-07
- Last Posted Date
- 2016-03-14
- Target Recruit Count
- 136966
- Registration Number
- NCT02518503
Safety of Fluvastatin-Celebrex Association in Low-grade and High Grade Optico-chiasmatic Gliomas
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Centre Oscar Lambret
- Target Recruit Count
- 20
- Registration Number
- NCT02115074
- Locations
- 🇫🇷
CHU Angers, Angers, France
🇫🇷Centre Hospitalier de Nancy, Vandoeuvre-les-Nancy, France
🇫🇷Centre Oscar Lambret, Lille, France
Novel Window of Opportunity Trial to Evaluate the Impact of Statins to Oppose Prostate Cancer
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2017-10-26
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 33
- Registration Number
- NCT01992042
- Locations
- 🇨🇦
University Health Network- The Princess Margaret Cancer Centre, Toronto, Ontario, Canada
The Role of the "Inflammatory/ Pathogen Burden" for Cardiac Ageing
- First Posted Date
- 2010-01-11
- Last Posted Date
- 2015-01-28
- Lead Sponsor
- Martin-Luther-Universität Halle-Wittenberg
- Target Recruit Count
- 96
- Registration Number
- NCT01045512
- Locations
- 🇩🇪
Martin-Luther-Universität Halle-Wittenberg, Medizinische Fakultät, Klinik und Poliklinik für Innere Medizin III, Universitätsklinikum Halle (Saale), Ernst-Grube-Strasse 40, Halle (Saale), Sachsen-Anhalt, Germany
Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2009-01-13
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 144
- Registration Number
- NCT00821574
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.